Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 56

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 56
---
 from Leerink Partners on the various counterparties, weighed the relative merits of each request, and decided to proceed with the proposals that
would most likely result in a successful transaction.

During such period, and in particular on May 22, 2025, the Transaction
Committee held a meeting that was also attended by members of management and representatives of Stikeman, Cooley and Leerink Partners. At this meeting, representatives of Stikeman and Cooley reviewed with the Transaction Committee the Board’s
fiduciary duties, and the Transaction Committee reviewed and discussed, with the advice of management and its advisors, the Company’s potential strategic alternatives, including the inbounds received and perceived interest from third parties
as at such date.

Of the 43 strategic counterparties contacted, 16 expressed interest across the Company’s three assets and held
meetings with management, with two counterparties (“Party A” and “Party B,” respectively) each submitting a non-binding proposal for lead asset RP-3467 and one counterparty (“Party C”) submitting for RP-1664 and camonsertib.

Of the 28 orthogonal merger counterparties contacted, 12 counterparties received a process letter and 4 submitted non-binding proposals. None were advanced into further diligence, and the process with these counterparties was terminated on May 30, 2025.

During this time, members of management and representatives of Stikeman, Cooley and Leerink Partners met regularly with the Transaction
Committee to receive guidance and direction on the outreach process and with the Board to provide them with periodic updates. Throughout, management kept the Transaction Committee informed of the cash position of the Company.

After additional diligence, analysis, and negotiations through July 2025, Party C which submitted a proposal for RP-1664 exited the process, while the Company continued negotiations and diligence with Party A and Party B for RP-3467.

31

On August 7, 2025, the Board held a regularly scheduled meeting, attended by members of
management, and representatives of Stikeman, Cooley and Leerink Partners, at which the Board discussed, together with management, the Company’s ongoing strategic review process and potential strategic alternatives, including pursuit of a
financial buyer transaction process.

After a robust outreach process, the Transaction Committee had concluded that there were no
compelling proposals emerging for a potential transaction for a sale of the Company as a going concern or asset sale or a reverse merger, such that the pursuit of a sale to a financial buyer